Breaking News, Collaborations & Alliances

RedHill and Cosmo Strengthen Manufacturing Agreements

Secures manufacturing capacity of Movantik for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RedHill Biopharma has entered agreements with Cosmo Pharmaceuticals to manufacture two key products: RedHill’s largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.   “Movantik is currently our biggest commercial product,” said Steven Thomasian, vice president of supply chain management, RedHill Biopharma. “This agreement streng...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters